Regeneron Pharmaceuticals Inc. (REGN) — RQD Stock Rating Cockpit
Regeneron Pharmaceuticals Inc. (REGN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Real cash coming in backs up reported profits (41% profit margin and healthy balance-sheet cushion).
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
2-of-3 JEV AI Jury Bullish on REGN
9.4% ROIC with 41.0% gross margin and 5.14% FCF yield.
Altman-Z 7.72 and Piotroski 8/9 pass balance-sheet audit.
Put/Call 0.84x with 22/40 institutional & insider flow.
- ✓Strong cash generator (41% profit margin)—profits are backed by real money, not accounting tricks.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live REGN Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
REGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on REGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for REGN. Explore sector supply chains on /butterfly.
REGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell REGN stock right now?
Regeneron Pharmaceuticals Inc. (REGN) currently earns a Roarable Rating of C+ (Hold — HOLD) with 67/100 RQD Confidence. Solid 41% profit margin (9% return on capital), mixed timing at 19x P/E—hold if owned, no rush to chase.
What is REGN's 12-month price target and RQD AI Jury consensus?
REGN's 12-month base price target is $851.93 (range $664.51 to $1005.28), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.